About CND261 CND261 is a bispecific antibody designed to target CD20 on B-cells and CD3 on T-cells, enabling T-cell mediated cytotoxicity against CD20-expressing B-cells.

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Recent advancements in dermatology have highlighted the crucial role of dermal T cell immunity in regulating hair follicle regeneration and addressing ...

Recent advancements in dermatology have highlighted the crucial role of dermal T cell immunity in regulating hair follicle regeneration and ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

TCE bispecific antibodies have a major advantage over typical monoclonal antibodies due to their potent targeted cytotoxic activity ... presenting cells via Fc-mediated processes such as ADCC, CDC, ...

A University of Alberta research team has identified a DNA structure that activates the immune system in cancer cells that ...